SI-BONE received FDA 510(k) clearance of a modified indication for the iFuse Implant System®, noting that clinical studies have demonstrated its ability to improve pain, patient function and quality of life. The revised indication is based on safety and effectiveness data from retrospective studies as well as three prospective clinical trials.
To date, >21,000 iFuse procedures have been performed worldwide to treat sacroiliac joint dysfunction.
Sources: SI-BONE, Inc.; ORTHOWORLD Inc.
SI-BONE received FDA 510(k) clearance of a modified indication for the iFuse Implant System®, noting that clinical studies have demonstrated its ability to improve pain, patient function and quality of life. The revised indication is based on safety and effectiveness data from retrospective studies as well as three prospective clinical trials.
...
SI-BONE received FDA 510(k) clearance of a modified indication for the iFuse Implant System®, noting that clinical studies have demonstrated its ability to improve pain, patient function and quality of life. The revised indication is based on safety and effectiveness data from retrospective studies as well as three prospective clinical trials.
To date, >21,000 iFuse procedures have been performed worldwide to treat sacroiliac joint dysfunction.
Sources: SI-BONE, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.